Abstract
Tamoxifen is one of the drugs most frequently used in breast cancer therapy. It binds mainly to intracellular receptors (mainly estrogen receptor alpha, ERα) and it plays an antagonist role to β-estrogen ligands avoiding uncontrolled cellular proliferation and growth. In our laboratories we have developed a novel fluorescent tamoxifen derivative, FLTX1, formed by the covalent binding of tamoxifen to NBD moiety, which is a common biomarker for lipids and hydrophobic environments. The new complex not only keeps the pharmacologic activity of tamoxifen but also adds a luminescent functionality to the drug, see Fig. 1a. Strikingly, FLTX1 lacks most of the secondary effects described for tamoxifen [1].
© 2017 IEEE
PDF ArticleMore Like This
Zhiyi Liu, Eugen Dhimolea, Antonio Varone, Constantine S. Mitsiades, and Irene Georgakoudi
OmM4D.2 Optical Molecular Probes, Imaging and Drug Delivery (OMP) 2017
Wei R. Chen
T1B.1 International Conference on Photonics and Imaging in Biology and Medicine (PIBM) 2017
Maximilian Koch, Johannes S. de Jong, Jürgen Glatz, Panagiotis Symvoulidis, Laetitia E. Lamberts, Arthur L.L. Adams, Mariëtte E.G. Kranendonk, Anton G.T. Terwisscha van Scheltinga, Michaela Aichler, Liesbeth Jansen, Jakob de Vries, Marjolijn N. Lub-de Hooge, Carolien P. Schröder, Annelies Jorritsma-Smit, Matthijs D. Linssen, Esther de Boer, Bert van der Vegt, Wouter B. Nagengast, Sjoerd G. Elias, Sabrina Oliveira, Arjen J. Witkamp, Willem P.Th.M. Mali, Elsken Van der Wall, P. Beatriz Garcia-Allende, Paul J. van Diest, Elisabeth G.E. de Vries, Axel Walch, Gooitzen M. van Dam, and Vasilis Ntziachristos
104110F European Conference on Biomedical Optics (ECBO) 2017